Posters

Macular OCT changes after anti-VEGF therapy for type 1 and aggressive posterior ROP

Poster Details

First Author: U.Balcı TURKEY

Co Author(s):    M. Erol   E. Suren                          

Abstract Details



Purpose:

To investigate the clinical and macular spectral-domain optical coherence tomography (SD-OCT) findings after IVR treatment for type 1 and aggressive posterior retinopathy of prematurity (ROP)

Setting:

Retrospective

Methods:

Charts of 1200 premature infants reviewed, 22 patients who received IVR injections due to having type 1 or aggressive posterior ROP and had a OCT image taken included in the study. The main outcome measures were changes in macular structure, changes in central foveal thickness and regression of ROP after ranibizumab therapy. Secondary outcome measures were the need for additional therapy, such as repeat injections or laser treatment.

Results:

Twelve male and 10 female infants were included in the study. Six patients had APROP (5 male, 1 female), The mean gestational age was 27.6 ± 1.8 weeks (range: 23 to 32 weeks). The range of PMA (post menstrual age) at type 1 or APROP diagnosis was 33 to 37 weeks. Forty eyes of 22 patients were treated with IVR as monotherapy. In these patients, plus disease regressed one week after IVR injection except for one patient, (mean follow-up: 13.4 ± 6.5 months). In ten eyes of six patients, recurrence of plus disease was noted. Both eyes of one patient were treated with a second IVR. Others were treated with laser photocoagulation. Recurrence time was between 7 and 10 weeks after IVR. Cystoid macular edema (CME) was observed in all patients but at various times in their follow-up periods. CME resolution was observed in all but 6 eyes at the end of the second month. All eyes with recurrence of ROP had hyperreflective foci in the vitreous or retina.

Conclusions:

We performed IVR injection to only one eye each of 4 patients. Delay in elipsoid zone formation was observed in the IVR injected eye when compared to the uninjected eye.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy